Security Snapshot

Rapport Therapeutics, Inc. - Common Stock, $0.001 par value per share (RAPP) Institutional Ownership

CUSIP: 75383L102

13F Institutional Holders and Ownership History from Q2 2024 to Q3 2026

13F reference period

Q3 2026

Institutions Reporting

120

Shares (Excl. Options)

37.46MFull value: 37,455,919 · shares · 30 Sep 2026

Price

$33.60

The headline uses the Q3 2026 reference period after its reporting deadline. Available reports may still be incomplete or amended.

Save this security page for your next review

Watchlists follow companies and investors, across their share classes. Bookmark this page to revisit this specific CUSIP and its quarterly holders. If you create an account from here, we will bring you back after verification.

Latest holder snapshot 5 signals
Portfolio coverage rank
0%
Share change
-645,989
Value change
-$36,259,773
Number of holders
120
Issuer context Names, identifiers, and filing context for this profile. 3 identity fields
Shares outstanding
47,998,457
SEC-reported price per share
$22.50
Insider filing price
$22.50
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Filing notes and source

Key facts

  • RAPP - Rapport Therapeutics, Inc. - Common Stock, $0.001 par value per share is tracked under CUSIP 75383L102.
  • 120 institutions reported positions in Q3 2026.
  • 6 significant owners is listed from Schedule 13D/13G reporting.

Change

  • Holder count moved from 160 to 120 between Q2 2026 and Q3 2026.
  • SEC-reported value moved from
    $2.13BFull value: $2,129,194,307 · USD · 30 Jun 2026
    to
    $1.26BFull value: $1,258,512,612 · USD · 30 Sep 2026
    .

Research use

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Evidence

Source: SEC Form 13F

Latest holder context comes from 120 institutions filings for Q3 2026.

Open SEC evidence

Security key

75383L102

13F reference period

Q3 2026

13F holders

120

13D/G owners

6

CIK / CUSIP context first

13D/G owners

Significant owners

Large-stake holder rows connected to Schedule 13D/G evidence.

Rows
6
Security
RAPP
Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Third Rock Ventures V, L.P. 13% -32% $261,709,477 -$35,615,682 6,280,525 -12% Third Rock Ventures V, L.P. 30 Jun 2026
Capital International Investors 6.1% $121,757,990 2,921,958 Capital International Investors 30 Jun 2026
Cormorant Asset Management, LP 5.1% -7.3% $82,572,706 -$6,720,000 2,457,521 -7.5% Cormorant Asset Management, LP 30 Sep 2026
BlackRock, Inc. 5% $72,741,637 2,397,549 BlackRock, Inc. 31 Dec 2025
Sofinnova Venture Partners XI, L.P. 4.2% $29,155,258 1,947,579 Dr. James I. Healy ("Healy") 11 Sep 2025
JOHNSON & JOHNSON 4.9% $53,000,690 1,784,517 JOHNSON & JOHNSON 30 Sep 2025
As of 30 Sep 2026, 120 institutional investors reported holding
37.46MFull value: 37,455,919 · shares · 30 Sep 2026
shares of Rapport Therapeutics, Inc. - Common Stock, $0.001 par value per share (RAPP). This represents 78% of the company’s total
48MFull value: 47,998,457 · shares · Stored outstanding share count
outstanding shares.

13F concentration

Top 25 institutional shareholders

Largest 13F positions for this security by reported shares and value.

Top holder share
71%
Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
TRV GP V, LLC 13% 6,280,525 44% $211,025,640
ARCH Venture Management, LLC 7.8% 3,728,738 7.8% $125,285,597
GOLDMAN SACHS GROUP INC 6.2% 2,973,796 0.01% $99,919,545
Capital International Investors 5.5% 2,653,640 0.02% $89,162,304
Cormorant Asset Management, LP 5.1% 2,457,521 5.5% $82,572,706
Sofinnova Investments, Inc. 4% 1,904,408 3.2% $63,988,109
JOHNSON & JOHNSON 3.7% 1,784,517 7.9% $59,959,771
Polar Capital Holdings Plc 3.3% 1,603,582 0.15% $53,880,355
VANGUARD CAPITAL MANAGEMENT LLC 3.3% 1,579,991 0% $53,087,698
BAKER BROS. ADVISORS LP 3.2% 1,547,090 0.25% $51,982,224
TRV GP VI, LLC 2% 969,218 13% $32,565,725
STATE STREET CORP 1.9% 916,471 0% $30,793,426
GEODE CAPITAL MANAGEMENT, LLC 1.8% 869,740 0% $29,230,030
PERCEPTIVE ADVISORS LLC 1.5% 724,342 0.46% $24,337,891
Siren, L.L.C. 1.3% 641,469 0.51% $21,553,358
ALLIANCEBERNSTEIN L.P. 1.3% 629,508 0.01% $21,151,469
Capital World Investors 1.1% 551,657 0% $18,535,675
Artisan Partners Limited Partnership 0.91% 437,608 0.03% $14,703,629
DIMENSIONAL FUND ADVISORS LP 0.84% 403,205 0% $13,545,550
VANGUARD PORTFOLIO MANAGEMENT LLC 0.76% 362,611 0% $12,183,730
ALGERT GLOBAL LLC 0.63% 303,720 0.12% $10,204,992
Sio Capital Management, LLC 0.61% 291,231 2.1% $9,785,362
KENNEDY CAPITAL MANAGEMENT LLC 0.52% 251,912 0.16% $8,464,243
VANGUARD FIDUCIARY TRUST CO 0.51% 246,306 0% $8,275,882
Casdin Capital, LLC 0.42% 200,000 0.29% $6,720,000

Quarter history

Institutional holders across reporting periods

Holder count, reported shares/value, and median price by quarter.

Periods
10
Headline period
Q3 2026
Rows shown
1-10 of 10
Period 13F Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2026 Q3 37,455,919 $1,258,512,612 -$36,259,773 $33.60 120
2026 Q2 51,271,114 $2,129,194,307 -$48,032,179 $41.67 160
2026 Q1 52,482,926 $1,641,485,641 +$41,369,429 $31.29 146
2025 Q4 51,084,271 $1,549,894,668 +$54,540,100 $30.34 144
2025 Q3 49,276,697 $1,463,478,389 +$335,895,056 $29.70 123
2025 Q2 38,494,803 $437,875,302 +$4,896,059 $11.37 81
2025 Q1 38,102,588 $382,320,591 +$11,241,443 $10.03 77
2024 Q4 36,577,539 $648,890,836 -$29,671 $17.74 69
2024 Q3 28,444,042 $581,877,476 +$37,552,009 $20.48 55
2024 Q2 25,558,517 $593,435,106 +$593,435,106 $23.26 35
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .